Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (111-120 of 377) with videos related to

Pageof 38
Sort By:
Anti-Cancer Drugs|February 12, 2009
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicityCecilia Nisticò, Emilio Bria, Vanja Vaccaro, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 2, 2019
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate CancerRoberto Iacovelli, Chiara Ciccarese, Matteo Brunelli, et al.
The Oncologist|March 13, 2020
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?Alice Avancini, Giulia Sartori, Anastasios Gkountakos, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 15, 2008
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II studyAlessandra Fabi, Mariangela Ciccarese, Giulio Metro, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 10, 2011
Maintenance therapy in NSCLC: why? To whom? Which agent?Silvia Novello, Michele Milella, Marcello Tiseo, et al.
Nutrients|August 9, 2020
The Facts about Food after Cancer Diagnosis: A Systematic Review of Prospective Cohort StudiesEmanuele Rinninella, Maria Cristina Mele, Marco Cintoni, et al.
Cancer|November 28, 2007
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trialsFederica Cuppone, Emilio Bria, Sunil Verma, et al.
Immunotherapy|June 10, 2017
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studiesChiara Ciccarese, Roberto Iacovelli, Emilio Bria, et al.
Expert Opinion on Pharmacotherapy|March 12, 2013
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicineSara Pilotto, Umberto Peretti, Silvia Novello, et al.
Cancers|December 3, 2020
Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant TherapyFilippo Lococo, Carolina Sassorossi, Dania Nachira, et al.
Pageof 38

Showing results (111-120 of 377) with videos related to

Sort By:
Pageof 38
Anti-Cancer Drugs|February 12, 2009
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicityCecilia Nisticò, Emilio Bria, Vanja Vaccaro, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 2, 2019
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate CancerRoberto Iacovelli, Chiara Ciccarese, Matteo Brunelli, et al.
The Oncologist|March 13, 2020
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?Alice Avancini, Giulia Sartori, Anastasios Gkountakos, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 15, 2008
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II studyAlessandra Fabi, Mariangela Ciccarese, Giulio Metro, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 10, 2011
Maintenance therapy in NSCLC: why? To whom? Which agent?Silvia Novello, Michele Milella, Marcello Tiseo, et al.
Nutrients|August 9, 2020
The Facts about Food after Cancer Diagnosis: A Systematic Review of Prospective Cohort StudiesEmanuele Rinninella, Maria Cristina Mele, Marco Cintoni, et al.
Cancer|November 28, 2007
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trialsFederica Cuppone, Emilio Bria, Sunil Verma, et al.
Immunotherapy|June 10, 2017
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studiesChiara Ciccarese, Roberto Iacovelli, Emilio Bria, et al.
Expert Opinion on Pharmacotherapy|March 12, 2013
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicineSara Pilotto, Umberto Peretti, Silvia Novello, et al.
Cancers|December 3, 2020
Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant TherapyFilippo Lococo, Carolina Sassorossi, Dania Nachira, et al.
Pageof 38